false000172312800017231282022-05-092022-05-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 9, 2022
AMNEAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3848532-0546926
(State or other jurisdiction
of incorporation)		(Commission File Number)(IRS Employer
Identification No.)
400 Crossing Blvd
Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (908) 947-3120
N/A
(Former Name or Former Address, if Changed Since Last Report) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: 
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, par value $0.01 per shareAMRXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.07
Submission of Matters to a Vote of Security Holders.

Amneal Pharmaceuticals, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”) on May 9, 2022. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockholders at the Annual Meeting as follows:
Proposal 1: To elect the following director nominees to hold office until the 2023 Annual Meeting of Stockholders and until their respective successors are elected and qualified:
  
For
  
Against
  
Abstain
  
Broker Non-Votes
 
Emily Peterson Alva
  
233,367,731
4,027,769
270,575
20,029,960
 
J. Kevin Buchi
  
200,540,414



36,874,511


251,150



20,029,960
 
Jeff George
  
199,259,620



38,156,822


249,633



20,029,960
 
John Kiely
  
193,546,651



43,852,884


266,540



20,029,960
 
Paul Meister
  
200,167,942


37,242,388


255,745



20,029,960
 
Ted Nark
  
207,399,477



30,001,444


265,154



20,029,960
 
Chintu Patel
  
236,380,089



1,187,228


98,758



20,029,960
 
Chirag Patel
  
236,348,727



1,243,120


74,228



20,029,960
 
Gautam Patel
  
233,108,078



4,481,987


76,010



20,029,960

Shlomo Yanai
  
236,247,636



1,285,233


133,206



20,029,960
 

Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers:

For
 
Against
 
Abstain
 
Broker Non-Votes
236,202,110
1,193,006
270,959
20,029,960

Proposal 3: To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022:

For
 
Against
 
Abstain
 
Broker Non-Votes
256,967,689

253,537
474,809

0


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 13, 2022
AMNEAL PHARMACEUTICALS, INC.
By:/s/ Jason B. Daly
Name:Jason B. Daly
Title:Executive Vice President, Chief Legal Officer and Corporate Secretary